For example, technical difficulties hinder the ability to capture targets with high GC content, such as CEBPA, which is associated with poor prognosis of AML, or repetitive genomic regions, such as FLT3-ITD, which is associated with poor prognosis of AML in the absence of NPM1 mutation [10, 12, 21–27]. The gene discussed is NPM1; the disease is acute myeloid leukemia.